Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI ‐Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2‐Low Status of Breast Cancer
Journal of Magnetic Resonance Imaging · 2023-11 · 58 (5) · 1603-1614
DOI: 10.1002/jmri.28628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Magnetic Resonance Imaging, online erschienen am 10.02.2023. Verfasst von Xiaoqian Bian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The First Affiliated Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Multiparametric MRI radiomics could distinguish human epidermal growth factor receptor 2 (HER2)‐positive from HER2‐negative breast cancers. However, its value for further distinguishing HER2‐low from HER2‐negative breast cancers has not been investigated.
Purpose
To investigate whether multiparametric MRI‐based radiomics can distinguish HER2‐positive from HER2‐negative breast cancers (task 1) and HER2‐low from HER2‐negative breast cancers (task 2). Study Type Retrospective. Population Task 1: 310 operable breast cancer patients from center 1 (97 HER2‐positive and 213 HER2‐negative); task 2: 213 HER2‐negative patients (108 HER2‐low and 105 HER2‐zero); 59 patients from center 2 (16 HER2‐positive, 27 HER2‐low and 16 HER2‐zero) for external validation. Field Strength/Sequence A 3.0 T/T1‐weighted contrast‐enhanced imaging ( T1CE ), diffusion‐weighted imaging ( DWI )‐derived apparent diffusion coefficient ( ADC ). Assessment Patients in center 1 were assigned to a training and internal validation cohort at a 2:1 ratio. Intratumoral and peritumoral features were extracted from T1CE and ADC. After dimensionality reduction, the radiomics signatures (RS) of two tasks were developed using features from T1CE (RS‐T1CE), ADC (RS‐ADC) alone and T1CE + ADC combination (RS‐Com). Statistical Tests Mann–Whitney U tests, the least absolute shrinkage and selection operator, receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA).
Results
For task 1, RS‐ADC yielded higher area under the ROC curve (AUC) in the training, internal, and external validation of 0.767/0.725/0.746 than RS‐T1CE (AUC = 0.733/0.674/0.641). For task 2, RS‐T1CE yielded higher AUC of 0.765/0.755/0.678 than RS‐ADC (AUC = 0.706/0.608/0.630). For both of task 1 and task 2, RS‐Com achieved the best performance with AUC of 0.793/0.778/0.760 and 0.820/0.776/0.711, respectively, and obtained higher clinical benefit in DCA compared with RS‐T1CE and RS‐ADC. The calibration curves of all RS demonstrated a good fitness. Data Conclusion Multiparametric MRI radiomics could noninvasively and robustly distinguish HER2‐positive from HER2‐negative breast cancers and further distinguish HER2‐low from HER2‐negative breast cancers. Evidence Level 3. Technical Efficacy Stage 2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, The First Affiliated Hospital of China Medical University, Shenyang, China.
- School of Intelligent Medicine, China Medical University, Shenyang, China.
ORCID-Profile: Lina Zhang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Bian, X., Du, S., Yue, Z., Gao, S., Zhao, R., Huang, G., Guo, L., Peng, C., & Zhang, L. (2023). Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI ‐Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2‐Low Status of Breast Cancer. Journal of Magnetic Resonance Imaging, 58(5), 1603-1614. https://doi.org/10.1002/jmri.28628
Vancouver
Bian X, Du S, Yue Z, Gao S, Zhao R, Huang G, et al. Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI ‐Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2‐Low Status of Breast Cancer. Journal of Magnetic Resonance Imaging. 2023;58(5):1603-1614. doi:10.1002/jmri.28628
BibTeX
@article{Bian2023,
author = {Bian, Xiaoqian and Du, Siyao and Yue, Zhibin and Gao, Si and Zhao, Ruimeng and Huang, Guoliang and Guo, Liangcun and Peng, Can and Zhang, Lina},
title = {Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI ‐Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2‐Low Status of Breast Cancer},
journal = {Journal of Magnetic Resonance Imaging},
year = {2023},
volume = {58},
number = {5},
pages = {1603--1614},
doi = {10.1002/jmri.28628}
}
EUVIMED